I know we're only supposed to comment on the articles but I've tried 3 different computers, 4 browsers, and two IP addresses and I still just get a blank white page. Even with all javascript enabled, etc. The Lancet jumped the shark in late 2019 and has only been getting worse. Their website is literally not performing it's function to distribute text.
At least I could still get the full article at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079373/
"Booster effectiveness relative to primary series was 26·2% (95% CI 23·6–28·6) against infection and 75·1% (40·2–89·6) against severe, critical, or fatal COVID-19, during 1-year follow-up after the booster."
That's not as bad as I thought it would be. The intramuscular's humoral) immunity against severe disease in the body serum and organs holds up pretty well. The protection against infection, which relies on upper respiratory mucosal immunity that injections into the arm don't give, are predictably low.
I really wish the USA was still funding vaccine research so that some of these intranasal booster trials could be sped up. I haven't heard much about India's approved iNCOVACC intranasal role-out (starting this past ~feb), but the papers on it's effectiveness against infection should be out soon.
At least I could still get the full article at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079373/
"Booster effectiveness relative to primary series was 26·2% (95% CI 23·6–28·6) against infection and 75·1% (40·2–89·6) against severe, critical, or fatal COVID-19, during 1-year follow-up after the booster."
That's not as bad as I thought it would be. The intramuscular's humoral) immunity against severe disease in the body serum and organs holds up pretty well. The protection against infection, which relies on upper respiratory mucosal immunity that injections into the arm don't give, are predictably low.
I really wish the USA was still funding vaccine research so that some of these intranasal booster trials could be sped up. I haven't heard much about India's approved iNCOVACC intranasal role-out (starting this past ~feb), but the papers on it's effectiveness against infection should be out soon.